FDA, Advisory Panel Agree: Post-Hoc Analyses Won't Fly

CDRH's critique of Guidant's post-hoc analysis of its Contak CD data sends a clear warning to sponsors who attempt to draw positive conclusions about one subgroup from an inconclusive clinical trial.